TRI 5.26% 2.0¢ trivarx ltd

Ann: Investor Presentation - February 2019, page-26

  1. 507 Posts.
    lightbulb Created with Sketch. 333
    Absolutely!

    I feel confident after speaking to Dave (New CEO). He is in control and ensured to control the cost to reduce the cash burn. At this stage his focus is it to obtain FDA regulatory clearance. 
 
watchlist Created with Sketch. Add TRI (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.